$CLX

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

Clorox (CLX) recalled 6.3 million units of scented Mistolin and Lestoil cleaners in Puerto Rico and the U.S. Virgin Islands due to potential Pseudomonas aeruginosa contamination. The stock fell 1.3% to $93.06. No injuries have been reported, and the recall's financial impact is unclear. Clorox's fiscal 2026 sales declined 5% to $6.72 billion, with adjusted EPS dropping 28%.

Clorox is recalling 6.3 million bottles of scented Mistolin and Lestoil cleaners in Puerto Rico and the U.S. Virgin Islands due to potential Pseudomonas aeruginosa contamination. The recall affects products with date codes starting 'PR01' and made between April 2025 and June 2026. Vulnerable users, such as those with weakened immune systems or medical devices, are at risk. No injuries have been reported. Clorox offers refunds for affected products.

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

Clorox (CLX) shares fell about 4% as investors cited margin pressure and cost concerns, including a 520 bps YoY Q4 gross margin drop to 41.3%. Analysts including RBC and HSBC cut FY27 estimates and price targets amid worries about flat underlying growth.

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

Clorox (CLX) stock rose 13.1% in a month after beating Q4 earnings and revenue estimates, with adjusted EPS of $1.66 and sales of $1.95B. The company expects fiscal 2027 sales growth of 13-14% and EPS of $5.70-$6.00, driven by GOJO acquisition and ERP benefits. However, margins remain pressured by inflation and softer demand, with gross margin declining to 41.3% in Q4. Organic sales growth is expected to be flat to slightly positive, excluding ERP effects.

Morgan Stanley, using NielsenIQ All Measured Outlets data, reported pet food and cat litter sales trends for the latest four-week period. Pet category growth rose slightly vs prior 12-week trends. Colgate-Palmolive, Freshpet, General Mills, J.M. Smucker, Mars, Nestle and Post Holdings showed differing YoY changes; Church & Dwight and Clorox led cat litter growth.

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.